Kissei Pharmaceutical Co., Ltd. (KSPHF)

OTCMKTS · Delayed Price · Currency is USD
26.97
-4.93 (-15.45%)
At close: Dec 8, 2025
Market Cap1.25B +18.3%
Revenue (ttm)607.79M +14.3%
Net Income90.15M +21.2%
EPS2.15 +27.2%
Shares Outn/a
PE Ratio13.89
Forward PEn/a
Dividend1.04 (3.87%)
Ex-Dividend DateMar 30, 2026
Volume400
Average Volume685
Open26.97
Previous Close31.90
Day's Range26.97 - 26.97
52-Week Range23.23 - 31.90
Beta-0.26
RSI56.04
Earnings DateJan 30, 2026

About Kissei Pharmaceutical

Kissei Pharmaceutical Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products primarily in Japan. The company offers Calogra tablets, for the treatment of ulcerative colitis; Tabneos capsules for the treatment of microscopic polyangiitis and granulomatous polyangiitis; Minirin Melt OD tablets; Corsuba Intravenous Dialysis Syringe for the treatment of chronic idiopathic thrombocytopenic purpura; Beova tablets for the treatment of overactive bladder treatment; and Darbepoetin Alfa BS injection JCR for the treatment of rena... [Read more]

Sector Healthcare
Founded 1946
Employees 1,778
Stock Exchange OTCMKTS
Ticker Symbol KSPHF
Full Company Profile

Financial Performance

In fiscal year 2025, Kissei Pharmaceutical's revenue was 88.33 billion, an increase of 16.87% compared to the previous year's 75.58 billion. Earnings were 11.96 billion, an increase of 7.18%.

Financial numbers in JPY Financial Statements